Zelluna ASA [ZLNA]: Annual Report 2025

25 Mar 2026 07:00 CET

Oslo, Norway, 25 March 2026 - Zelluna ASA, a company pioneering allogeneic "off-
the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the
treatment of solid cancers, announces that the Board of Directors of Zelluna ASA
has approved the Annual Report for 2025.

A PDF version of the Annual Report, as well as the report in European Single
Electronic Format (ESEF), are attached to this release. The Annual Report is
also available on the company's website: www.zelluna.com
(http://www.zelluna.com)

This information is subject to the disclosure requirements pursuant to Section
5-12 in the Norwegian Securities Trading Act.

For further information, please contact:

Anders Tuv, Chairman of the Board of Directors of Zelluna ASA
Email: at@radforsk.no (mailto:at@radforsk.no)
Phone: +47 982 06 826

Namir Hassan, CEO, Zelluna ASA
Email: namir.hassan@zelluna.com (mailto:namir.hassan@zelluna.com)
Phone: +44 7720 687608

Geir Christian Melen, CFO, Zelluna ASA
Email: geir.christian.melen@zelluna.com
(mailto:geir.christian.melen@zelluna.com)
Phone: +47 913 02 965

More information:
Access the news on Oslo Bors NewsWeb site

669228_Zelluna Annual Report 2025.pdf
669228_254900B4VALJZR9TL744-2025-12-31-1-en.zip